Design of the Knowledge Database and Model Database for Rare Diseases
Institute of Medical Information,CAMS & PUMC,Beijing 100020,China
*Corresponding author:HU Hongpu,Professor,Doctoral supervisor;E-mail:hu.hongpu@imicams.ac.cn
[1]贾瑾萌. 基于多组学整合与网络分析的罕见病机制研究[D]. 上海:华东师范大学,2019.
[2]刘立立,贺冰洁,陈暐烨,等. 罕见骨骼疾病患者及家属健康信息获取途径与需求调查[J]. 中华疾病控制杂志,2020,24(10):1219-1223. DOI:10.16462/j.cnki.zhjbkz.2020.10.021.
LIU L L,HE B J,CHEN W Y,et al. Survey of access and demands of health information in patients with rare bone diseases and their families[J]. Chin J Dis Control Prev,2020,24(10):1219-1223. DOI:10.16462/j.cnki.zhjbkz.2020.10.021.
[3]NI X,SHI T. The challenge and promise of rare disease diagnosis in China[J]. Sci China Life Sci,2017,60(7):681-685. DOI:10.1007/s11427-017-9100-1.
[4]张睿,郑周荣,陈薇,等. 罕见病辅助诊断临床决策支持系统综述[J]. 中国数字医学,2021,16(5):86-90. DOI:10.3969/j.issn.1673-7571.2021.05.019.
ZHANG R,ZHENG Z R,CHEN W,et al. Review of auxiliary diagnosis clinical decision support system of rare diseases[J]. China Digital Medicine,2021,16(5):86-90. DOI:10.3969/j.issn.1673-7571.2021.05.019.
[5]VINARTI R A,HEDERMAN L M. A knowledge-base for a personalized infectious disease risk prediction system[J]. Stud Health Technol Inform,2018,247(10):531-535. DOI:10.1016/j.eswa.2019.04.042.
[6]CHEN H M,ENGKVIST O,WANG Y H,et al. The rise of deep learning in drug discovery[J]. Drug Discov Today,2018,23(6):1241-1250. DOI:10.1016/j.drudis.2018.01.039.
[7]徐超,何静云,方丽,等.罕见病相关体外诊断试剂的临床试验要求[J]. 国际检验医学杂志,2020,41(24):3045-3049. DOI:10.3969/j.issn.1673-4130.2020.24.025.
XU C,HE J Y,FANG L,et al. Clinical trial requirements of rare disease related in vitro diagnostic reagents[J]. Int J Lab Med,2020,41(24):3045-3049. DOI:10.3969/j.issn.1673-4130.2020.24.025.
[8]张仪,王增阁,王剑. 罕见病实验室诊断技术的进展[J]. 检验医学,2021,36(2):122-129,118. DOI:10.3969/j.issn.1673-8640.2021.02.002.
ZHANG Y,WANG Z G,WANG J. Progress in laboratory diagnosis of rare diseases[J]. Laboratory Medicine,2021,36(2):122-129,118. DOI:10.3969/j.issn.1673-8640.2021.02.002.
[9]TORRENT-FARNELL J,COMELLAS M,POVEDA J L,et al. The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain:a Delphi consensus[J]. Health Policy,2018,122(6):590-598. DOI:10.1016/j.healthpol.2018.03.002.
[10]刘丽华,赵建中,谢松梅,等. 罕见病药物的临床审评:挑战与思考[J]. 国际药学研究杂志,2019,46(9):673-678. DOI:10.13220/j.cnki.jipr.2019.09.005.
LIU L H,ZHAO J Z,XIE S M,et al. Clinical evaluation of drugs for rare diseases:challenges and considerations[J]. J Int Pharm Res,2019,46(9):673-678. DOI:10.13220/j.cnki.jipr.2019.09.005.
[11]石鑫淼,刘徽,王琳,等. 基于中国1 500万余例次住院病例的121种罕见病现况分析[J]. 中华医学杂志,2018,98(40):3274-3278. DOI: 10.3760/cma.j.issn.0376-2491.2018.40.012.
SHI X M,LIU H,WANG L,et al. Study on the current situation of China's first list of rare diseases based on 15 million hospitalizations[J]. Natl Med J China,2018,98(40):3274-3278. DOI: 10.3760/cma.j.issn.0376-2491.2018.40.012.
[12]JAMES K N,PHADKE S,WONG T C,et al. Artificial intelligence in the genetic diagnosis of rare disease[J]. Adv Mol Pathol,2020,3(11):143-155. DOI:10.1016/j.yamp.2020.07.013.
[13]RIA?O D,PELEG M,TEIJE A. Ten years of knowledge representation for health care(2009—2018):topics,trends,and challenges[J]. Artif Intell Med,2019,100(9):101713. DOI:10.1016/j.artmed.2019.101713.
[14]OGAERTS B,VENNEKENS J,DENECKER M. Safe inductions and their applications in knowledge representation[J]. Artif Intell,2018,259(6):167-185. DOI:10.1016/j.artint.2018.03.008.
[15]CZECH M,BARAN-KOOIKER A,ATIKELER K,et al. A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries[J]. Front Public Health,2019,7(1):416. DOI:10.3389/FPUBH.2019.00416.
[16]D?RING J H,LAMPERT A,HOFFMANN G F,et al. Thirty years of orphan drug legislation and the development of drugs to treat rare seizure conditions:a cross sectional analysis[J]. PLoS One,2017,11(8):e0161660. DOI:10.1371/journal.pone.0161660.
[17]高星,雷行云,王岩,等. 基层卫生服务决策支持系统构建[J]. 医学信息学杂志,2019,40(4):24-27. DOI:10.3969/j.issn.1673-6036.2019.04.006.
GAO X,LEI X Y,WANG Y,et al. Building of decision support system for primary health care service[J]. Journal of Medical Informatics,2019,40(4):24-27. DOI:10.3969/j.issn.1673-6036.2019.04.006.
[18]LI C H,MING K,LIM K,et al. Predicting microbial interactions through computational approaches[J]. Methods,2016,102(6):12-19. DOI:10.1016/j.ymeth.2016.02.019.
[19]李艳. 规范化罕见疾病临床资源数据库的建立及数据分析[D]. 济南:济南大学,2015.
[20]顾坚磊,江建平,田园,等. 人工智能技术的应用:罕见病临床决策系统的需求、现状与挑战[J]. 第二军医大学学报,2018,39(8):819-825. DOI:10.16781/j.0258-879x.2018.08.0819.
GU J L,JIANG J P,TIAN Y,et al. Application of artificial intelligence technology:clinical demands,status and challenges of clinical decision support system for rare diseases[J]. Academic Journal of Second Military Medical University,2018,39(8):819-825. DOI:10.16781/j.0258-879x.2018.08.0819.
LIU L L,HE B J,CHEN W Y,et al. Survey of access and demands of health information in patients with rare bone diseases and their families[J]. Chin J Dis Control Prev,2020,24(10):1219-1223. DOI:10.16462/j.cnki.zhjbkz.2020.10.021.